SpringWorks Therapeutics, Inc. (SWTX)
Jul 1, 2025 - SWTX was delisted (reason: acquired by Merck KGaA)
46.99
0.00 (0.00%)
Inactive · Last trade price on Jun 30, 2025
SpringWorks Therapeutics Revenue
SpringWorks Therapeutics had revenue of $49.09M in the quarter ending March 31, 2025, with 133.68% growth. This brings the company's revenue in the last twelve months to $219.67M, up 730.42% year-over-year. In the year 2024, SpringWorks Therapeutics had annual revenue of $191.59M with 3,417.33% growth.
Revenue (ttm)
$219.67M
Revenue Growth
+730.42%
P/S Ratio
15.92
Revenue / Employee
$596,929
Employees
368
Market Cap
3.54B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 191.59M | 186.14M | 3,417.33% |
Dec 31, 2023 | 5.45M | - | - |
Dec 31, 2022 | - | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | 35.00M | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionSWTX News
- 2 months ago - European Commission Grants Approval of OGSIVEO® (nirogacestat) for the Treatment of Adults with Desmoid Tumors - GlobeNewsWire
- 3 months ago - European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN - GlobeNewsWire
- 3 months ago - Merck KGaA, Darmstadt, Germany Completes Acquisition of SpringWorks Therapeutics to Accelerate Sustainable Growth of its Healthcare Business - Business Wire
- 4 months ago - SpringWorks Therapeutics Receives Positive CHMP Opinion for Nirogacestat for the Treatment of Adults with Desmoid Tumors - GlobeNewsWire
- 4 months ago - SPRINGWORKS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of SpringWorks Therapeutics, Inc. - SWTX - Business Wire
- 5 months ago - SpringWorks Therapeutics Receives Positive CHMP Opinion for Mirdametinib for the Treatment of Adult and Pediatric Patients with NF1-PN - GlobeNewsWire
- 6 months ago - ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of SpringWorks Therapeutics, Inc. - PRNewsWire
- 6 months ago - Germany's Merck Agrees to Buy US Biotech SpringWorks Therapeutics for Almost $4B - Investopedia